White Paper

State Of The Union For CGTx Advanced Medicines

Source: Precision ADVANCE
GettyImages-1302573302 cell gene union

Over the last several years, the cell and gene therapy (CGTx) sector has flourished. However, recent public market downturns have undermined investor confidence. Recently, industry leaders participated in a roundtable featuring insights from diverse industry perspectives on the current state of the CGTx sector; the investment landscape; scientific and technical advances; progress in drug development, manufacturing, regulatory, pricing, and reimbursement; and more.

The panel discussion, hosted by Endpoints News and sponsored by Precision ADVANCE, featured the following industry leaders:

  • Dave Greenwald, Vice President, Business Development, Deerfield Management
  • Rajul Jain, Managing Director, Vida Ventures
  • Joseph La Barge, Chief Executive Officer, Apertura Gene Therapy
  • Adrian Woolfson, Executive Chairman, President and Co-Founder, Replay Bio
  • Phil Cyr, Executive Vice President, Precision Value & Health

Moderated by Anshul Mangal, President of Project Farma and Precision ADVANCE, gain insight from the collective’s take on key trends in CGTx in 2023 and beyond.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene